Immune Checkpoint Inhibitor–Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents
Results of this study suggest that ICI-D is a rare but morbid condition that varies based on the combination of ICIs with other agents.
Authors
- Zoe Quandt (ORCID: https://orcid.org/0000-0002-4568-4368)
- Vanessa Hill
- Sapir Tessler
- Joe Dib
- M. Anderson
- Jason Burian
- Shanda Finnigan (ORCID: https://orcid.org/0000-0002-0555-8965)
- Elad Sharon (ORCID: https://orcid.org/0000-0002-2512-3539)
- Abdul Rafeh Naqash (ORCID: https://orcid.org/0000-0001-7622-720X)
- D C Davidson (ORCID: https://orcid.org/0009-0008-5239-030X)
- Megan Othus
Institutions
- University of California, Santa Barbara (US)
- University of California, San Francisco (US)
- University of Michigan (US)
- University of Oklahoma Medical Center (US)
- Cancer Research And Biostatistics (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- University of Maryland, College Park (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1001/jamaoncol.2025.5594
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00